Tracking Genomic Cancer Evolution for Precision Medicine: The Lung TRACERx Study

Mariam Jamal‐Hanjani(Royal London Hospital), A. Hackshaw(University College London), Yenting Ngai(Cancer Research UK), Jacqui Shaw(University of Leicester), Caroline Dive(Cancer Research UK Manchester Institute), Sergio A. Quezada(London Cancer), Gary Middleton(Heartlands Hospital), Elza de Bruin(University College London), John Le Quesne(University of Leicester), Seema Shafi(University College London), Mary Falzon(University College London), Stuart Horswell(Cancer Research UK), Fiona Blackhall(The Christie Hospital), Iftekhar Khan(Cancer Research UK), Sam M. Janes(Royal London Hospital), M. Nicolson(Aberdeen Royal Infirmary), David Lawrence(University College Hospital at Westmoreland Street), Martin Förster(University College London), Dean A. Fennell(University of Leicester), Siow Ming Lee(Royal London Hospital), J.F. Lester(Velindre Cancer Centre), Keith M. Kerr(Aberdeen Royal Infirmary), S. Muller(University Hospitals of Leicester NHS Trust), Natasha Iles(Cancer Research UK), Sean D. Smith(Cancer Research UK), Nirupa Murugaesu(Royal London Hospital), Richard Mitter(Cancer Research UK), Max Salm(Cancer Research UK), Aengus Stuart(Cancer Research UK), Nik Matthews, Haydn Adams(University Hospital Llandough), Tanya Ahmad(Royal London Hospital), Richard Attanoos(University Hospital Llandough), Jonathan Bennett(University of Leicester), Nicolai J. Birkbak(Technical University of Denmark), Richard Booton(University of Manchester), Ged Brady(Cancer Research UK Manchester Institute), Keith Buchan(Aberdeen Royal Infirmary), Arrigo Capitano(University College London), Mahendran Chetty(Aberdeen Royal Infirmary), Mark Cobbold(University of Birmingham), Philip Crosbie(North Manchester General Hospital), Helen Davies(University Hospital Llandough), Alan Denison(University of Aberdeen), Madhav Djearman(Heartlands Hospital), Jacki Goldman, Tom Haswell, Leena Dennis Joseph(Manchester University), Malgorzata Kornaszewska(University Hospital Llandough), Matthew Krebs(Cancer Research UK Manchester Institute), Gerald Langman(Heartlands Hospital), Mairead MacKenzie, Joy Millar(Aberdeen Royal Infirmary), Bruno Morgan(University of Leicester), Babu Naidu(Heartlands Hospital), Daisuke Nonaka(Manchester University), Karl S. Peggs(University College London), Catrin Pritchard(University of Leicester), Hardy Remmen(Aberdeen Royal Infirmary), Andrew Rowan, Rajesh Shah, Elaine Smith, Yvonne Summers(The Christie Hospital), Magali N. Taylor(Royal London Hospital), Selvaraju Veeriah(London Cancer), David Waller(University Hospitals of Leicester NHS Trust), Ben Wilcox(University of Birmingham), Maggie Wilcox, Ian Woolhouse(University of Birmingham), Nicholas McGranahan, Charles Swanton(Royal London Hospital)
PLoS Biology
July 8, 2014
10.1371/journal.pbio.1001906
Cited by 258Open Access
Full Text

Abstract

The importance of intratumour genetic and functional heterogeneity is increasingly recognised as a driver of cancer progression and survival outcome. Understanding how tumour clonal heterogeneity impacts upon therapeutic outcome, however, is still an area of unmet clinical and scientific need. TRACERx (TRAcking non-small cell lung Cancer Evolution through therapy [Rx]), a prospective study of patients with primary non-small cell lung cancer (NSCLC), aims to define the evolutionary trajectories of lung cancer in both space and time through multiregion and longitudinal tumour sampling and genetic analysis. By following cancers from diagnosis to relapse, tracking the evolutionary trajectories of tumours in relation to therapeutic interventions, and determining the impact of clonal heterogeneity on clinical outcomes, TRACERx may help to identify novel therapeutic targets for NSCLC and may also serve as a model applicable to other cancer types.

Related Papers

No related papers found

Powered by citation graph analysis